[Can we apply gene therapy in the treatment of Parkinson patients?].
Problems associated with a long-term application of L-dopa to treat Parkinsons disease, have prompted interest in developing alternative therapeutic strategies. Parkinsons disease is a suitable candidate for neurological gene therapy, given our knowledge of the functional anatomy of the striato-nigral system. Recently, much effort was devoted to the administration of trophic factors to injured neurons, especially using glial cell line-derived factor (DGNF). Various aspects of this approach are discussed in this study.
Sela
B A
BA
Institute of Chemical Pathology, Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel.
D015316:Genetic Therapy; D051100:Glial Cell Line-Derived Neurotrophic Factor; D006801:Humans; D009414:Nerve Growth Factors / Q000235:genetics / Q000627:therapeutic use; D009419:Nerve Tissue Proteins / Q000235:genetics / Q000627:therapeutic use; D010300:Parkinson Disease / Q000235:genetics* / Q000628:therapy*
C495039:GDNF protein, human; D051100:Glial Cell Line-Derived Neurotrophic Factor; D009414:Nerve Growth Factors; D009419:Nerve Tissue Proteins